Published in Cancer Surv on January 01, 1985
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res (1971) 13.16
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med (1995) 9.72
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet (2001) 6.11
Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol (1989) 5.44
Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet (2004) 2.96
Low-dose risk assessment. Radiat Res (2007) 2.88
Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol (2000) 2.71
Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab (1986) 2.70
Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. Int J Radiat Oncol Biol Phys (2000) 2.58
Repair of potentially lethal radiation damage in vitro and in vivo. Radiology (1973) 2.43
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol (2005) 2.39
Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J Natl Cancer Inst (1995) 2.35
Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet (1997) 2.33
European Code Against Cancer and scientific justification: third version (2003). Ann Oncol (2003) 2.17
The link between local recurrence and distant metastases in human breast cancer. Int J Radiat Oncol Biol Phys (1999) 2.10
Application of the LQ model to the interpretation of absorbed dose distribution in the daily practice of radiotherapy. Radiother Oncol (1991) 2.01
Cell proliferation kinetics in five human solid tumors. Cancer (1968) 1.92
Relation between the pathological nature and the growth rate of human tumors. Eur J Cancer (1971) 1.92
Second cancer risk following testicular cancer: a follow-up study of 1,909 patients. J Clin Oncol (1993) 1.91
Increased incidence of solid malignant tumors after bone marrow transplantation for severe aplastic anemia. Blood (1991) 1.88
A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol (1992) 1.79
Long-term risk of sarcoma following radiation treatment for breast cancer. Int J Radiat Oncol Biol Phys (1991) 1.77
The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. Br J Cancer (1998) 1.75
ICRP publication 112. A report of preventing accidental exposures from new external beam radiation therapy technologies. Ann ICRP (2009) 1.73
Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. Br J Cancer (1984) 1.71
RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma. Eur J Cancer (2005) 1.69
The relationship between growth rate, labelling index and histological type of human solid tumours. Eur J Cancer (1973) 1.68
Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer (1985) 1.66
Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study. J Natl Cancer Inst (2001) 1.63
Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors. J Clin Oncol (1988) 1.61
[Growth rate and natural history of breast cancer]. Bull Cancer (1976) 1.61
Predictive value of in vitro radiosensitivity parameters in head and neck cancers and cervical carcinomas: preliminary correlations with local control and overall survival. Int J Radiat Oncol Biol Phys (1993) 1.60
Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. Ann Oncol (2010) 1.59
Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer (2008) 1.57
Can internal mammary chain treatment decrease the risk of death for patients with medial breast cancers and positive axillary lymph nodes? Cancer (1990) 1.55
Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol (1987) 1.53
Prognostic value of tumor regression during radiotherapy for head and neck cancer: a prospective study. Int J Radiat Oncol Biol Phys (1995) 1.52
Specificity of the functional interactions of the beta-adrenergic receptor and rhodopsin with guanine nucleotide regulatory proteins reconstituted in phospholipid vesicles. J Biol Chem (1985) 1.52
The long-term prognostic significance of the thymidine labelling index in breast cancer. Int J Cancer (1984) 1.51
The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood (1998) 1.49
Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol (1995) 1.49
L.H. Gray Medal lecture: cell kinetics and radiation oncology. Int J Radiat Oncol Biol Phys (1982) 1.46
Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms' Tumor Trial and Study. J Clin Oncol (2001) 1.45
Prospective randomized comparison of single-dose versus hyperfractionated total-body irradiation in patients with hematologic malignancies. J Clin Oncol (2000) 1.44
Radiotherapy after ovarian transposition: ovarian function and fertility preservation. Int J Radiat Oncol Biol Phys (1993) 1.44
Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol (1994) 1.44
Postoperative pelvic radiotherapy with or without elective irradiation of para-aortic nodes and liver in rectal cancer patients. A controlled clinical trial of the EORTC Radiotherapy Group. Radiother Oncol (2001) 1.43
The clinical spectrum and treatment of primary non-Hodgkin's lymphoma of the stomach. Ann Oncol (1993) 1.42
Presence of mutations in all three ras genes in human thyroid tumors. Oncogene (1990) 1.42
Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer (2002) 1.41
Carcinoma cell leukemia. Blood (1996) 1.40
Effectiveness of preoperative chemotherapy in Wilms' tumor: results of an International Society of Paediatric Oncology (SIOP) clinical trial. J Clin Oncol (1983) 1.39
Chemoradiotherapy for localized non-Hodgkin's lymphoma. N Engl J Med (1998) 1.39
Kinetics of cell proliferation of an experimental tumor. Cancer Res (1967) 1.38
The predictive value of cell kinetic measurements in a European trial of accelerated fractionation in advanced head and neck tumors: an interim report. Int J Radiat Oncol Biol Phys (1990) 1.37
Age has no impact on acute and late toxicity of curative thoracic radiotherapy. Radiother Oncol (1998) 1.34
Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol (1998) 1.31
Kinetic parameters and the course of the disease in breast cancer. Cancer (1981) 1.30
External radiotherapy in thyroid cancers. Cancer (1985) 1.28
A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol (1983) 1.27
Tomoscintigraphy for detecting gastrointestinal and medullary thyroid cancers: first clinical results using radiolabelled monoclonal antibodies against carcinoembryonic antigen. Br Med J (Clin Res Ed) (1982) 1.25
Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol (1994) 1.25
Radiation therapy as local treatment in Ewing's sarcoma. Results of the Cooperative Ewing's Sarcoma Studies CESS 81 and CESS 86. Cancer (1991) 1.18
Detection of activated ras oncogenes in human thyroid carcinomas. Oncogene (1988) 1.12
Non-Hodgkin's malignant lymphomata of upper digestive and respiratory tract: natural history and results of radiotherapy. Br J Cancer Suppl (1975) 1.11
The causes of cancer in France. Ann Oncol (2008) 1.11
Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group. J Clin Oncol (1996) 1.10
Tumour lysis syndrome and acute renal failure in Burkitt's lymphoma. Description of 2 cases and a review of the literature on prevention and management. Neth J Med (1994) 1.08
The 5a-chromosome abnormality in haematological disorders: a collaborative study of 34 cases from the Netherlands. Br J Haematol (1982) 1.08
Measuring progress against cancer in Europe: has the 15% decline targeted for 2000 come about? Ann Oncol (2003) 1.08
Conformal radiotherapy (CRT) planning for lung cancer: analysis of intrathoracic organ motion during extreme phases of breathing. Int J Radiat Oncol Biol Phys (2001) 1.07
Isolated primary oesophageal involvement by lymphoma: a rare cause of dysphagia: two case histories and a review of other published data. Gut (1993) 1.05
Differentiated thyroid carcinoma in childhood: long term follow-up of 72 patients. J Clin Endocrinol Metab (1987) 1.05
Intraventricular methotrexate therapy of leptomeningeal metastasis from breast carcinoma. Neurology (1983) 1.05
Prognostic factors in primary gastrointestinal non-Hodgkin's lymphoma. A multivariate analysis, report of 106 cases, and review of the literature. Cancer (1989) 1.04
In vitro parameters and treatment outcome in head and neck cancers treated with surgery and/or radiation: cell characterization and correlations with local control and overall survival. Int J Radiat Oncol Biol Phys (1994) 1.03
Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospective study. Radiology (1996) 1.03
A simulation model of the natural history of human breast cancer. Br J Cancer (1985) 1.02
Primary lymphoma of mucosa associated lymphoid tissue (MALT) in the parotid gland. Clin Otolaryngol Allied Sci (1993) 1.02
Non-Hodgkin's lymphomata: clinical features in relation to histology. Br J Cancer Suppl (1975) 1.01
Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol (1987) 1.01
Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol (2000) 1.01
Increased risk of lung cancer, non-Hodgkin's lymphoma, and leukemia following Hodgkin's disease. J Clin Oncol (1989) 1.01
[Data on the rate of growth of human tumors]. Bull Cancer (1971) 1.00